Skip To Main Content
B. You on Muck Rack

B. You

As seen in: ScienceDirect, Annals of Oncology, EJSO - European Journal of Surgical Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to B. You’s profile

Articles by B. You

Optimizing the d-band center of Pd/CoPcS-Ti3C2Tx to enhance SOD/CAT-mimicking activities in the treatment of osteoarthritis

|
By B. You, H. Sun, X. Yuan, W. Hou
| ScienceDirect Verified
Osteoarthritis (OA) is the primary cause of disability among the elderly, affecting over 400 million people globally [1], [2]. However, there are no effective medications to slow or reverse disease progression currently [3], [4], [5].
Open in Who Shared Issue with article?

ENDOLA : A GINECO-GINEGEPS French NCI sponsored phase I/II trial to assess the safety and efficacy of metronomic cyclophosphamide, metformin and OLAparib in recurrent advanced/metastatic ENDometrial cancer patients

|
By B. You, Institut Gustave Roussy, A. Dugue, A. Leary
| Annals of Oncology Verified
ENDOLA : A GINECO-GINEGEPS French NCI sponsored phase I/II trial to assess the safety and efficacy of metronomic cyclophosphamide, metformin and OLAparib in recurrent advanced/metastatic ENDometrial cancer patients B. You1, A. Dugue2, A. Leary3, M. Rodrigues4, P. Follana5, D. Maucort-Boulch6, S. Verane7, M. Tod8 and G.
Open in Who Shared Issue with article?

Non pegylated liposomal doxorubicin (npld, myocettm) + carboplatin (cb) in patients (pts) with ovarian cancer in late relapse (oclr): a phase 2 gineco study

|
By B. You, Pierre Bénite, F. Joly, I. L. Ray-Coquard
| Annals of Oncology Verified
Non pegylated liposomal doxorubicin (npld, myocettm) + carboplatin (cb) in patients (pts) with ovarian cancer in late relapse (oclr): a phase 2 gineco study B. You1, F. Joly2, I.L. Ray-Coquard3, C. El Kouri4, A. Mercier-Blas5, D. Berton-Rigaud6, E. Kalbacher7, O. Cojocarasu8, M. Fabbro9, J. Cretin10, A. Zannetti11, S. Abadie-Lacourtoisie12, D. Mollon13, A-C. Hardy-Bessard14, M. Provansal15 and G.
Open in Who Shared Issue with article?

The predictive value of the CA-125 modeled kinetic parameter KELIM is validated in 3 independent datasets (AGO-OVAR 7 & 9; ICON 7 AGO/GINECO/GCIG trials)

|
By B. You, Pierre Bénite, O. Colomban, M. Tod
| Annals of Oncology Verified
The predictive value of the CA-125 modeled kinetic parameter KELIM is validated in 3 independent datasets (AGO-OVAR 7 & 9; ICON 7 AGO/GINECO/GCIG trials) B.M. You1, O. Colomban1, M. Tod1, I.L. Ray-Coquard2, A. Lortholary3, A.C. Hardy-Bessard3, A. Du Bois4, J. Huober5, W. Meier6, C. Kurzeder4 and J.
Open in Who Shared Issue with article?

Inclusion Of Elderly Patients In Oncology Clinical Trials

|
By O. Le Saux, C. Falandry, H. K. Gan, B. You, G. Freyer
| Annals of Oncology Verified
BACKGROUND Physicians need clinical trials assessing benefits and harms of treatments to avoid under-treatment or over-treatment of elderly patients. The main objectives of this report were to examine how data regarding elderly oncology patients was presented in medical literature; and to assess the evolution of this presentation between two time periods.
Open in Who Shared Issue with article?
Show More